Skip to main content

Home/ Cancer/ Group items tagged immunotherapy

Rss Feed Group items tagged

Matti Narkia

CANCER VACCINES AND IMMUNOTHERAPY - lefeurope.com - 0 views

  •  
    Cancer immunotherapies, including cancer vaccines, are novel investigational cancer therapies. In contrast to chemotherapy and radiotherapy regimens that are often associated with severe side effects, cancer immunotherapy stimulates the body's immune system and natural resistance to cancer, thus offering a gentler means of cancer treatment that is less damaging to the rest of the body. Surgery is generally (but not always) performed, prior to immunotherapy, to remove most of the tumor (Hanna MG, Jr. et al 2001; Jocham D et al 2004). Vaccination or immunotherapy prompts the immune system to kill residual cancer cells that persist after surgery and could result in the cancer recurring.
Matti Narkia

Combination Immunotherapy of Squamous Cell Carcinoma of the Head and Neck: A Phase 2 Tr... - 0 views

  •  
    Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51. PMID: 10722007
Matti Narkia

Technology Review: Implant Makes Cells Kill Cancer - 0 views

  •  
    A new approach to cancer treatment called immunotherapy could spare patients at least some of the grueling battery of chemotherapy treatments by retraining the body's own defenders--the cells of the immune system--to recognize and destroy tumors. Now researchers at Harvard University have developed a simple way to do this inside the body: a polymer implant attracts and trains immune-system cells to go after cancer. The experimental approach has shown great success in animal studies, increasing the survival rate of mice with a deadly melanoma from 0 to 90 percent. The implant could also be used to treat diseases of the immune system such as arthritis and diabetes, and, potentially, to train other kinds of cells, including stem cells used to repair damage to the body.
Matti Narkia

Inhibition of suppressor T lymphocytes (Ts) by cimetidine. - J Immunol. 1987 May - 0 views

  •  
    Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. J Immunol. 1987 May 1;138(9):2760-3. PMID: 2952721 Cyclophosphamide (CY) is the most extensively studied inhibitor of suppressor T lymphocyte (Ts) function. However, repeated administration of CY can abrogate sensitization. Therefore, we were interested in identifying noncytotoxic inhibitors of Ts function as adjuncts in the immunotherapy of Ts-inducing murine tumors. The effect of cimetidine (a histamine type 2 receptor antagonist) and diphenhydramine (a histamine type 1 receptor antagonist) on the Ts mediating tolerance to 2,4-dinitrofluorobenzene was studied. We report our data regarding the specific inhibition of Ts by cimetidine.
Matti Narkia

IL-7/IL-15 increases immune response, inhibits tumor development, metastases - 0 views

  •  
    MedWire News: Intralesional injection of interleukin (IL)-7 and IL-15 enhances the effects of radiofrequency thermal ablation (RFA) in inhibiting tumor development and metastases, animal study results show. RFA, used for the treatment of solid tumors and known for its localized tumor effects, may activate immune responses and thereby reduce the risk for local tumor recurrence or distant metastases through T cell stimulation. However, studies have suggested that additional adjuvant immunotherapy may improve the efficacy of RFA. This preclinical study, reported in Breast Cancer Research and Treatment, was conducted to evaluate the effect of addition of the cytokines IL-7 and IL-15 to RFA in models of breast cancer.
Matti Narkia

Cancer immunology - Wikipedia, the free encyclopedia - 0 views

  •  
    Cancer immunology is the study of interactions between the immune system and cancer cells (also called tumors or malignancies). It is also a growing field of research that aims to discover innovative cancer immunotherapies to treat and retard progression of this disease. The immune response, including the recognition of cancer-specific antigens is of particular interest in this field as knowledge gained drives the development of new vaccines and antibody therapies. For instance in 2007, Ohtani published a paper finding tumour infiltrating lymphocytes to be quite significant in human colorectal cancer.[1] The host was given a better chance at survival if the cancer tissue showed infiltration of inflammatory cells, in particular lymphocytic reactions. The results yielded suggest some extent of anti-tumour immunity is present in colorectal cancers in humans.
Matti Narkia

CD40L - a multipotent molecule for tumor therapy. - Bentham Science Publishers - Endocr... - 0 views

  •  
    CD40L - a multipotent molecule for tumor therapy. Loskog A, Tötterman TH. Endocr Metab Immune Disord Drug Targets. 2007 Mar;7(1):23-8. Review. PMID: 17346201
Matti Narkia

Multiple roles for CD4+ T cells in anti-tumor immune responses. - Wiley InterScience ::... - 0 views

  •  
    Multiple roles for CD4+ T cells in anti-tumor immune responses. Kennedy R, Celis E. Immunol Rev. 2008 Apr;222:129-44. Review. PMID: 18363998 DOI: 10.1111/j.1600-065X.2008.00616.x
Matti Narkia

Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells ... - 0 views

  •  
    Interleukin 2-mediated conversion of ovarian cancer-associated CD4+ regulatory T cells into proinflammatory interleukin 17-producing helper T cells. Leveque L, Deknuydt F, Bioley G, Old LJ, Matsuzaki J, Odunsi K, Ayyoub M, Valmori D. J Immunother. 2009 Feb-Mar;32(2):101-8. PMID: 19238008 doi: 10.1097/CJI.0b013e318195b59e Thus, although the impact of TH17 cells on the evolution of EOC remains to be established, our data suggest that local IL-2 treatment in ovarian cancer may result in the conversion of tumor-associated Treg into TH17 cells, relieve Treg-mediated suppression, and contribute to enhance antitumor immunity.
Matti Narkia

DEVELOPMENT OF HPV VACCINES FOR HPV-ASSOCIATED HEAD AND NECK SQUAMOUS CELL CARCINOMA --... - 0 views

  •  
    Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Devaraj K, Gillison ML, Wu TC. Crit Rev Oral Biol Med. 2003;14(5):345-62. Review. PMID: 14530303
Matti Narkia

Antitumor Activity of Human Papillomavirus Type 16 E7-Specific T Cells against Virally ... - 0 views

  •  
    Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Albers A, Abe K, Hunt J, Wang J, Lopez-Albaitero A, Schaefer C, Gooding W, Whiteside TL, Ferrone S, DeLeo A, Ferris RL. Cancer Res. 2005 Dec 1;65(23):11146-55. PMID: 16322265
1 - 11 of 11
Showing 20 items per page